Answers are grounded in this paper and cite their sources.
Therapies for cystic fibrosis have been limited to alleviating clinical manifestations, and although the duration and quality of patients' lives have improved, cystic fibrosis continues to inflict major burdens and shorten lives.1 In this issue of the Journal, Accurso and colleagues2 have taken a different tack, directly targeting the defective cystic fibrosis transmembrane conductance regulator (CFTR) with a new drug that appears to be safe and to work in vivo. This research represents a milestone along the pathway of discovery leading to better preventions, treatments, and cures. It also illustrates the usefulness of genetic testing in identifying a select subgroup . . .
No takes yet. Share an insight, caveat, or question.
Michael J. Welsh (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: